Sei Investments Co. Grows Position in Xenon Pharmaceuticals Inc. $XENE

Sei Investments Co. boosted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.8% during the 1st quarter, Holdings Channel reports. The fund owned 114,381 shares of the biopharmaceutical company’s stock after acquiring an additional 70,523 shares during the quarter. Sei Investments Co.’s holdings in Xenon Pharmaceuticals were worth $6,652,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in XENE. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth approximately $56,637,000. Wellington Management Group LLP raised its holdings in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Xenon Pharmaceuticals by 1,968.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after purchasing an additional 820,608 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after purchasing an additional 700,000 shares during the last quarter. Finally, Commodore Capital LP lifted its position in shares of Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after purchasing an additional 700,000 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.91% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $62.26 on Tuesday. The stock’s 50-day moving average is $59.46 and its two-hundred day moving average is $53.64. The firm has a market cap of $6.02 billion, a price-to-earnings ratio of -13.25 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 1 year low of $30.65 and a 1 year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting the consensus estimate of ($1.17). During the same period in the previous year, the company earned ($0.83) earnings per share. As a group, research analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on XENE shares. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Royal Bank Of Canada upped their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Needham & Company LLC dropped their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.